Scarica l'app Stockscreener
2.70
11.57%
0.28
Dopo l'orario di chiusura:
2.64
-0.06
-2.22%
Mural Oncology Plc Borsa (MURA) Ultime notizie
Mural Oncology (MURA) Shares Skyrocket Amid Major Corporate Shift - Stocks Telegraph
BlackRock discloses stake in Mural Oncology By Investing.com - Investing.com Canada
Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives - MSN
Mass. biotech company cuts 90% of workforce - Boston.com
Form 8.3Mural Oncology plc - Business Wire
BlackRock discloses stake in Mural Oncology - Investing.com
Promising Pharmaceutical Stocks To Consider – April 15th - Defense World
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
BlackRock discloses 1.76% stake in Mural Oncology By Investing.com - Investing.com South Africa
MURA Soars as it Explores Strategic Options Post Cancer Study Failures - TradingView
LMR Partners LLP discloses 2.89% stake in Mural Oncology - Investing.com
Mural shuts down lead programme and slashes 90% of staff - Yahoo Finance
Mural Oncology Sees Unusually High Options Volume (NASDAQ:MURA) - Defense World
Mural Oncology halts nemvaleukin trials, seeks strategic options By Investing.com - Investing.com South Africa
Biotech Company Sees Stock Boost Following Major Strategy Shift - The Globe and Mail
Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On? - Benzinga
Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize
Raymond James cuts Mural Oncology target to $4, retains outlook By Investing.com - Investing.com UK
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Massachusetts biotech company cuts 90% of its workforce - NBC Boston
Mural Oncology cuts 90% of staff, pulls plug on cancer drug - The Business Journals
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
Mural Oncology Shares Jump as it Seeks Strategic Alternatives; Co. Discontinues Nemvaleukin Alfa Development - MarketScreener
Mural Oncology halts nemvaleukin trials, seeks strategic options - Investing.com
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
Mural Oncology Ends Nemvaleukin Program, Begins Strategic Review - Nasdaq
Mural Oncology Announces Plans To Explore Strategic Alternatives - MarketScreener
Mural Oncology Skyrockets on News of Strategic Shake-Up - Wall Street Pit
Mural Oncology to Explore Strategic Alternatives, Cut Workforce by 90%; Shares Jump Pre-Bell - MarketScreener
Why MURA Stock Goes Parabolic Today - Own Snap
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Failed Cancer Trial Forces Mural Oncology to Halt Development and Cut 90% of Workforce - Stock Titan
Research Analysts’ Recent Ratings Updates for Mural Oncology (MURA) - Defense World
Raymond James Financial Inc. Makes New Investment in Mural Oncology plc (NASDAQ:MURA) - Defense World
IL-2 ADding contenders in eczema strategy - BioWorld MedTech
Spin-Off Research Slashes Mural Oncology Valuation - Forbes
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer - Curetoday
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
40,025 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Virtu Financial LLC - Defense World
HC Wainwright Comments on Mural Oncology Q1 Earnings - Defense World
Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects - Seeking Alpha
HC Wainwright Lowers Mural Oncology (NASDAQ:MURA) Price Target to $6.00 - Defense World
Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals
Mural Oncology stock target cut to $6 at H.C. Wainwright By Investing.com - Investing.com UK
Mural Oncology downgraded to Hold from Buy at JonesResearch - TipRanks
Raymond James downgrades Mural Oncology after ovarian cancer failure - TipRanks
Mural Oncology (NASDAQ:MURA) Downgraded by Raymond James to Outperform - Defense World
Mural Oncology (NASDAQ:MURA) Given Hold Rating at Jones Trading - Defense World
Mural Oncology (NASDAQ:MURA) Downgraded to “Equal Weight” Rating by Morgan Stanley - Defense World
Raymond James cuts Mural Oncology stock rating, slashes target to $6 - Investing.com UK
Morgan Stanley cuts Mural Oncology stock rating to Equal-weight By Investing.com - Investing.com UK
Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57% - Clinical Trials Arena
Mural Oncology downgraded to Equal Weight from Overweight at Morgan Stanley - TipRanks
Mural Oncology halts ovarian cancer drug development By Investing.com - Investing.com South Africa
Mural Oncology sinks on nemvaleukin miss in ovarian cancer - BioWorld MedTech
Mural Oncology halts ovarian cancer trial By Investing.com - Investing.com South Africa
US Stocks Mixed; Core & Main Posts Downbeat Earnings - Benzinga
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges - Benzinga
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Jones Trading cuts Mural Oncology stock rating to hold By Investing.com - Investing.com UK
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):